The Final Stages of Biosimilar Development: Aligning CMC Packages with EMA Expectations

The Situation: Late-stage biosimilar approaching EMA and MHRA engagement

A biosimilars developer with a portfolio of monoclonal antibodies and recombinant proteins was preparing for European and UK market entry.  Programmes were in late-stage development, with PPQ data available or in preparation for pivotal clinical studies. 

While substantial CMC data had been generated across process development, analytical characterisation and stability, there were inconsistencies in how this information was presented. In several cases, summary claims were not adequately supported by underlying data, creating risk in the context of EMA and MHRA review. 

Given the proximity to submission, targeted support was required to assess the robustness of the CMC packages, engage with the EMA and MHRA to address key deficiencies. 

GRA Solution: Aligning CMC data with program strategy

Multiple experienced GRA CMC and regulatory Consultants provided integrated CMC and regulatory support across multiple programmes. 

• CMC gap analysis: Structured review of upstream, downstream, analytical and stability data against EMA and MHRA expectations with prioritisation of critical risks  

• Module 3 restructuring: Re-writing and alignment of quality summaries to ensure consistency, clarity and appropriate linkage between data and conclusions 

• Data re-analysis and positioning: Evaluation of existing datasets, including comparability and characterisation with refinement of the biosimilarity narrative 

• EMA and MHRA interaction support: Preparation of scientific advice materials and targeted questions to enable effective engagement with the agencies  

• Mitigation planning: Definition of pragmatic actions to address identified gaps, aligned to programme stage and timelines  

• Cross-functional coordination: Integration of analytical, process and regulatory activities through GRA-led project management 

Value Added: De-risked programmes whilst enabling EMA and MHRA submissions for market entry 

GRA helped transform technically complete yet inconsistently presented data packages into high-quality, submission-ready dossiers aligned with EMA and MHRA expectations. 

• Positive EMA scientific advice was obtained, providing a clear pathway to submission 

• Major objections were avoided reducing regulatory risks 

• Programmes progressed to submission with appropriate positioning 

• European and UK market entry strategy was supported 

GRA bridged technical delivery and regulatory expectations, enabling packages with weaknesses to be strengthened into approvable submissions that reduced late-stage development risk. 

Regulatory Affairs, CMC, Assays & QC, Formulation Development, Project Management